Fragile X Syndrome

• CGG Repeat Expansion and Gene Silencing: The FMR1 gene normally contains 5-44 CGG repeats in its 5' untranslated region. When the repeat number expands to >200 copies (full mutation), this triggers DNA hypermethylation of the FMR1 promoter region, leading to transcriptional silencing and complete loss of FMRP expression. Premutation carriers (55-200 CGG repeats) may produce FMRP at reduced levels, and some develop fragile X-associated tremor/ataxia syndrome (FXTAS) through a distinct gain-of-function mechanism involving toxic mRNA accumulation. The triplet repeat is particularly unstable during female meiosis, where expansions are most likely to occur, explaining the phenomenon of genetic anticipation and progressive disease severity across generations.

• Loss of FMRP Function and Altered Synaptic Plasticity: FMRP is an RNA-binding protein that regulates translation of specific mRNAs at the synapse, particularly those encoding proteins essential for dendritic spine formation and synaptic transmission. FMRP normally suppresses translation of these target mRNAs (including PSD-95, GKAP, and LIMK1) by binding to their 5' UTRs; loss of FMRP results in excessive protein synthesis and dysregulation of synaptic architecture. This leads to the pathognomonic finding of excessive, immature dendritic spines with abnormal morphology (long, thin, tortuous spines) rather than the normal stubby, mushroom-shaped spines seen in healthy brains. These morphological abnormalities persist even into adulthood in FXS, contributing to cognitive inflexibility and perseverative behaviors.

• Disrupted Metabotropic Glutamate Receptor (mGluR) Signaling: The mGluR theory of FXS posits that loss of FMRP's inhibitory effect on translation leads to excessive synthesis of mGluR-dependent proteins (particularly IP3 receptors and ryanodine receptors involved in intracellular calcium mobilization). This results in exaggerated mGluR-mediated long-term depression (LTD), a synaptic weakening mechanism that normally requires FMRP for proper regulation. The excessive LTD causes inappropriate synaptic pruning and destabilization of synaptic connections, contributing to cognitive deficits. This mechanism explains why mGluR antagonists (such as AFQ056/mavoglurant) are being investigated as potential therapeutic agents—they counteract the excessive mGluR signaling present in FXS.

• Altered GABAergic Inhibition and Hyperexcitability: FXS brains exhibit reduced GABAergic inhibition due to decreased expression of GABA-A receptors and alterations in GABAergic interneuron development. This creates an imbalance in the excitatory-inhibitory (E-I) balance, tilting toward a hyperexcitable state. The resulting increased cortical hyperexcitability manifests as seizures (which occur in 10-20% of FXS patients), auditory hypersensitivity, and tactile sensitivity. Genetic animal models demonstrate abnormal pattern separation in the hippocampus secondary to these GABAergic abnormalities, directly contributing to cognitive impairment.

• Impaired Experience-Dependent Plasticity and Learning: The constellation of dendritic spine abnormalities, dysregulated mGluR signaling, and altered inhibitory tone creates a brain that is unable to properly encode and consolidate memories through normal synaptic mechanisms. This results in profound difficulties with learning and cognitive flexibility—individuals with FXS can acquire factual knowledge but struggle with applying concepts in new contexts or modifying behavior based on feedback. The cerebellar dysfunction also frequently observed in FXS contributes to difficulties with motor learning and coordination.

• **CGG Trinucleotide Repeat Expansion in FMR1 Gene**: This is the primary and essentially only direct genetic cause of classic Fragile X syndrome. The expansion occurs in the 5' untranslated region of the FMR1 gene on chromosome Xq27.3. The repeat is highly unstable during meiosis, particularly during female gametogenesis, where large expansions from the permutation to full mutation occur in approximately 5% of transmissions. Males with full mutations invariably express the full phenotype due to hemizygosity, while female carriers show variable expression depending on X-inactivation patterns (lyonization). Advanced paternal age is not a risk factor for FXS, as males cannot transmit large expansions to daughters.

• Premutation Carriers and Genetic Anticipation: Individuals carrying 55-200 CGG repeats (premutation) have intermediate risk and may develop fragile X-associated primary ovarian insufficiency (FXPOI) in females or fragile X-associated tremor/ataxia syndrome (FXTAS) in older males. Female premutation carriers have a >50% risk of transmitting a full mutation to offspring, while males with premutations have a lower risk of full mutation transmission. The phenomenon of genetic anticipation describes worsening severity across generations as CGG repeats expand—grandmothers carrying 70 repeats may be unaffected, their daughters with 100-150 repeats might have mild intellectual disability, and their sons with 250+ repeats experience severe intellectual disability.

• X-Linked Inheritance with Variable Penetrance: The condition follows X-linked dominant inheritance, meaning affected males have a 100% chance of passing the mutation to daughters (who will be carriers) and 0% to sons. Heterozygous females may be affected with milder phenotypes or even unaffected depending on skewed X-inactivation, where preferential inactivation of the normal X chromosome in early development results in greater expression of the mutant allele. This X-inactivation pattern is random and early in development, making female phenotypes highly variable and sometimes more severe than expected from the mutation status alone.

• Intellectual Disability: This is the cardinal feature, present in virtually all males with full mutations and many females. In males, the degree ranges from mild learning disability (IQ 40-70) to severe intellectual disability (IQ <40), with a mean IQ approximately 40-50. Females typically present with mild to moderate intellectual disability or learning disorders, though some may be unaffected if X-inactivation favors the normal allele. The cognitive profile is characteristic, with relatively preserved verbal abilities compared to visual-spatial and mathematical reasoning; patients often exhibit better language comprehension than production, and perseveration and behavioral inflexibility are prominent cognitive features distinguishing FXS from other causes of intellectual disability.

• Autism Spectrum Disorder Features: Between 50-60% of males with FXS meet criteria for autism spectrum disorder, making this the single strongest genetic association with autism. Characteristic behaviors include social anxiety and social withdrawal (often more prominent than the social reciprocity deficits of idiopathic autism), hand stereotypies (hand flapping, hand biting), and repetitive speech patterns including echolalia and perseverative speech. Sensory sensitivities are nearly universal, with marked hypersensitivity to auditory stimuli (often severe enough to warrant earplugs in public settings), tactile defensiveness, and visual sensitivity to bright lights.

• Physical Dysmorphic Features: Recognizable facial features evolve with age and are often not apparent in infancy but become more prominent by late childhood and into adulthood. Classic features include long, narrow face with prominent ears (often described as "ears that stick out"), high arched palate, dental crowding, and a prominent chin. Macro-orchidism (enlarged testes, typically >15 mL) is nearly pathognomonic in adult males and post-pubertal adolescents, though absent in prepubertal boys. Connective tissue features including pectus excavatum or carinatum, hyperextensible joints, and skin picking are common, reflecting the underlying collagen and connective tissue involvement from FMRP dysfunction.

• Speech and Language Disorders: Speech is typically delayed in FXS, with expressive language more severely affected than receptive. Speech may be rapid, cluttered, and perseverative in quality, with characteristic features including tangled speech (garbled articulation), stuttering-like disfluency, and difficulty with pragmatic language despite reasonable vocabulary. Selective mutism occurs in some children, particularly in social situations, contrasting with more normal speech in familiar settings—this is more characteristic of FXS than idiopathic speech delay and reflects the prominent social anxiety component.

• Behavioral and Psychiatric Features: Anxiety disorders are nearly universal, manifesting as social phobia, generalized anxiety, and specific situational anxieties (school refusal is common). Mood symptoms including depression may emerge in adolescence and adulthood. Attention-deficit/hyperactivity disorder (ADHD) is present in 80-90% of affected males, manifesting with impulsivity, hyperactivity, and distractibility. Aggressive and self-injurious behaviors can occur, particularly during periods of anxiety or sensory overload, though are less severe than in some other genetic syndromes. Emotional regulation is prominently impaired, with rapid mood shifts and difficulty recovering from emotional upset.

• Motor and Coordination Problems: Developmental motor milestones are typically delayed, with gross motor skills more impaired than fine motor skills. Hypotonia is common in infancy and early childhood, often requiring physical therapy. Gait abnormalities including broad-based gait, toe-walking, and poor coordination persist into adulthood. About 10-15% of individuals develop seizures, most commonly generalized tonic-clonic seizures or absence seizures, with peak onset in late childhood and early adolescence.

• Female Heterozygote Presentation: Females with full mutations demonstrate tremendous phenotypic variability depending on X-inactivation patterns. Some are completely asymptomatic and identified only through family screening, while others present with intellectual disability equal in severity to affected males. More commonly, females present with learning disabilities (particularly in mathematics), attention problems, and anxiety disorders without significant intellectual disability. Premutation females may be completely unaffected cognitively but present with primary ovarian insufficiency, infertility, or premature menopause (fragile X-associated primary ovarian insufficiency, FXPOI) in their 30s-40s.

• Molecular Genetic Testing - CGG Repeat Analysis: The gold standard diagnostic test is molecular genetic testing by PCR and Southern blot analysis to quantify CGG repeat number in the FMR1 gene. PCR can reliably detect repeat numbers up to approximately 200 repeats; Southern blot is required for accurate detection of full mutations (>200 repeats) because the repeat instability and methylation prevent reliable PCR amplification of very large expansions. Sensitivity is essentially 100% for detecting full mutations in males, and the test can simultaneously assess methylation status (hypermethylation confirms full mutation and gene silencing). The interpretation includes classification as: normal (5-44 repeats), intermediate/gray zone (45-54 repeats, at minimal risk for expansion), premutation (55-200 repeats), and full mutation (>200 repeats). Indications for testing include: intellectual disability or developmental delay of unknown etiology, autism spectrum disorder, ADHD, learning disability (especially mathematics), family history of intellectual disability or FXS, premature ovarian insufficiency in women, and tremor/ataxia in older males.

• Fragile X Mental Retardation Protein (FMRP) Expression Testing: Immunocytochemistry or flow cytometry can detect absence of FMRP expression in lymphocytes, providing functional confirmation of gene silencing. This test is most useful in females where CGG repeat results may be ambiguous due to mosaicism (some cells with full mutation, others with premutation), because FMRP levels directly correlate with clinical severity. FMRP expression is absent in >99% of males with full mutations but variably reduced in females depending on X-inactivation. This test is less commonly used as a primary diagnostic tool but may be valuable in unusual presentations or when repeat number testing is inconclusive.

• Clinical Diagnosis Criteria: While molecular testing is definitive, clinical diagnosis should be considered in the presence of: intellectual disability or autism spectrum disorder with anxiety, sensory sensitivities, and characteristic behavioral features; long narrow face, prominent ears, macro-orchidism (in males); or family history of X-linked intellectual disability or FXS. The diagnostic criteria from the American Academy of Pediatrics recommend genetic testing for all children with autism spectrum disorder, as FXS accounts for 2-3% of autism cases. No scoring system captures all cases, but the combination of intellectual disability + autism features + anxiety + sensory sensitivities in a male should prompt immediate FXS testing.

• Differential Diagnosis Considerations: Other causes of X-linked intellectual disability (XLID) include CDKL5-related disorder (presents with infantile spasms and severe early developmental regression), PCDH19-related epilepsy (more prominent seizure phenotype), ARX-related conditions (infantile spasms), SYN1 mutations, and OPHN1 mutations. Rett syndrome (MECP2 mutations) presents with apparently normal development followed by regression at 6-18 months, distinct from the developmental delay present from infancy in FXS. Klinefelter syndrome (XXY) may present with learning disability and mild intellectual disability but lacks the characteristic autism features, sensory hypersensitivity, and macro-orchidism of FXS. Angelman syndrome presents with more severe intellectual disability, ataxia, and characteristic EEG abnormalities. The behavioral profile (prominent anxiety, sensory sensitivity, autism features, preserved relative to expected intellectual level) and characteristic physical features make FXS relatively distinctive from other genetic causes.

• Behavioral and Developmental Interventions (First-Line): Early intervention services (speech-language pathology, occupational therapy, physical therapy, and special education) initiated in infancy provide the strongest evidence for improved outcomes and should be offered to all children with FXS regardless of medication status. Speech-language therapy addresses the characteristic speech patterns, pragmatic language deficits, and selective mutism. Applied behavioral analysis (ABA) is particularly beneficial for reducing challenging behaviors and teaching social skills; a minimum of 15-20 hours per week has shown benefit, though intensity can be titrated to individual needs. Cognitive-behavioral therapy (CBT) adapted for intellectual disability level is effective for anxiety management and emotional regulation in verbal individuals. Occupational therapy addresses sensory processing difficulties through sensory integration techniques, providing strategies for managing auditory and tactile hypersensitivity (desensitization, use of noise-reducing devices, weighted clothing). Family-centered approaches involving parental coaching in behavior management improve outcomes significantly.

• Pharmacological Management of ADHD and Attention Problems: Stimulant medications (methylphenidate, amphetamine salts, lisdexamfetamine) are first-line for ADHD symptoms and are tolerated well in most FXS patients, contrary to historical concerns about exacerbating anxiety. Standard pediatric dosing applies (methylphenidate 5-20 mg BID, amphetamine salts 5-20 mg BID),

Neurologic

• Seizures: cortical hyperexcitability from reduced GABAergic tone and excess mGluR-driven excitation; most are focal or generalized tonic-clonic and often remit by adulthood. Signaled by staring spells, nocturnal events, or new regression in an already delayed child. Status epilepticus is an emergency — benzodiazepine first, then a second-line IV antiseizure agent per American Epilepsy Society status epilepticus guidance.
• Sleep disturbance/obstructive sleep apnea: high-arched palate, midface configuration, and hypotonia narrow the upper airway; snoring with daytime irritability or worsening behavior should prompt polysomnography.

Sensory and systemic

• Recurrent otitis media with conductive hearing loss: eustachian tube dysfunction from connective tissue laxity; because expressive language is already the weakest domain, unrecognized effusion compounds language delay. AAP health supervision guidance for fragile X emphasizes aggressive audiologic surveillance and low threshold for tympanostomy referral.
• Strabismus and refractive error: common and treatable; untreated strabismus risks amblyopia.
• Mitral valve prolapse and aortic root dilation: elastin-poor connective tissue; usually clinically silent, detected as a mid-systolic click — echocardiography if a murmur or click is heard.
• Orthopedic sequelae of joint hypermobility: pes planus, scoliosis, recurrent joint subluxation.

Treatment-related

• Stimulants: appetite suppression, growth deceleration, insomnia, and worsened irritability or tics; monitor growth curves at every visit.
• SSRIs: behavioral activation and disinhibition are especially common in FXS; the FDA boxed warning for increased suicidality in children and adolescents applies, mandating close early follow-up. Serotonin syndrome (hyperthermia, clonus, autonomic instability) is an emergency.
• Atypical antipsychotics (e.g., aripiprazole, risperidone) for aggression/self-injury: weight gain and metabolic syndrome, hyperprolactinemia, extrapyramidal symptoms, and tardive dyskinesia; neuroleptic malignant syndrome — rigidity, hyperthermia, elevated CK — is an emergency requiring drug withdrawal and supportive cooling.

Family-level

• Cascade complications in relatives: an unrecognized premutation predicts FXPOI (infertility, early menopause) in mothers/aunts and FXTAS (intention tremor, ataxia, executive decline) in grandfathers.

• The stem's giveaway triad: a school-aged or adolescent boy with intellectual disability plus long narrow face, large protruding ears, and macro-orchidism, layered on gaze aversion, hand-flapping, and hand-biting. Add joint hypermobility and a mid-systolic click.
• Single best next step: targeted FMR1 DNA testing (PCR for repeat sizing plus methylation analysis, with Southern blot for large expansions). Do not choose karyotype, and know the classic distractor — chromosomal microarray does not detect trinucleotide repeat expansions, so a normal microarray never excludes FXS. Cytogenetic culture in folate-deficient medium showing the fragile site at Xq27.3 is historical and is a wrong answer today.
• The association examiners test most: FXS is the most common inherited cause of intellectual disability and the most common single-gene cause of autism spectrum disorder; the American Academy of Pediatrics supports FMR1 testing in the evaluation of unexplained developmental delay, intellectual disability, or ASD.
• Anticipation is maternal: full mutations arise almost exclusively when a premutation mother transmits an unstable expansion. An affected or premutation father passes his X to every daughter and no son, and his repeat generally does not expand to a full mutation — so "transmitting male" grandfathers are a favorite stem device.
• Premutation ≠ mild fragile X — it is a different disease: 55–200 repeats cause FXTAS (intention tremor, gait ataxia, parkinsonism in older men; middle cerebellar peduncle T2 hyperintensity) and FXPOI (menopause before 40). Mechanism is toxic RNA gain-of-function, not FMRP loss.
• Macro-orchidism is post-pubertal. Its absence in a 4-year-old does not argue against the diagnosis.
• Molecular one-liner: >200 CGG repeats → promoter hypermethylation → FMR1 silencing → no FMRP → unchecked mGluR-dependent translation → long, thin, immature dendritic spines.
• Management distractor: there is no FDA-approved disease-modifying drug; early intervention and behavioral therapy are the answer over any pharmacologic "cure."